- $83.18m
- -$57.35m
- 20
- 41
- 48
- 29
Annual income statement for Allovir, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.165 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 26.9 | 71.3 | 170 | 171 | 200 |
Operating Profit | -26.7 | -71.3 | -170 | -171 | -200 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.8 | -69.8 | -171 | -169 | -191 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.8 | -69.8 | -172 | -169 | -190 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.8 | -69.8 | -172 | -169 | -190 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.8 | -69.8 | -172 | -169 | -190 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.345 | -1.13 | -2.74 | -2.2 | -1.71 |
Dividends per Share |